Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180699 | 1.00 | PGD (0.33) | PGDSLC22A6CACNA2D1CACNB3CACNA1C | |
| SCHEMBL4180706 | 1.00 | PGD (0.33) | PGDSLC22A6CACNA2D1CACNB3CACNA1C | |
| SCHEMBL9622524 | 0.85 | — | — | |
| SCHEMBL6484089 | 0.84 | ALDH1A1 (0.39) | TDP1 | |
| SCHEMBL6496531 | 0.84 | ALDH1A1 (0.39) | TDP1 | |
| SCHEMBL21234118 | 0.82 | — | — | |
| SCHEMBL4702274 | 0.82 | — | — | |
| SCHEMBL9805186 | 0.82 | — | — | |
| SCHEMBL2636857 | 0.82 | SMN1; SMN2 (0.35) | PGDSLC22A6ADRA1ATDP1 | |
| SCHEMBL4317387 | 0.81 | GABRP (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| CN-107709301-B | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2021-06-22 | — | — | CN | disclosed |
| EP-1970360-B1 | Method for producing alcohols | TAKASAGO PERFUMERY CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-7569735-B2 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL CORPORATION | 2008-09-18 | — | — | US | disclosed |
| EP-1970360-A1 | Method for producing alcohols | Takasago International Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1159263-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000050391-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | MERCK & CO., INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5332807-A | Process of producing 8A- and 9A-azalide antibiotics | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1994015617-A1 | 8A-AZA AND 9A-AZA MACROLIDE ANTIBIOTICS, AND A PROCESS FOR PRODUCING SAME AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5149462-A | Used as ferroelectric liquid crystal | MITSUBISHI RAYON COMPANY LTD. (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0409066-A2 | Optically active compound for liquid crystal and its use | MITSUBISHI RAYON COMPANY, LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | PGD 173/4885SLC22A6 303/4885CACNA2D1 4295/4885 |
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | LPXN, LIPE, MLX | PGD 225/4885SLC22A6 4131/4885CACNA2D1 1325/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | PGD 150/4885SLC22A6 451/4885CACNA2D1 3997/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | PGD 150/4885SLC22A6 451/4885CACNA2D1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.